8　亟待解决的问题

综上所述,关于氯吡格雷抵抗现象还有许多问题逐渐显现,亟待解决。首先,根据血小板聚集实验的结果能否预测将来发生心血管事件的风险。其次,不同的检测方法之间结果的一致性没有保证。第三,根据特定的试验得出结论之后应该采取何种治疗措施以改善临床预后尚无报道。第四,发生氯吡格雷抵抗的确切原因还不清楚。第五,国内对氯吡格雷抵抗的研究不多,中国人氯吡格雷抵抗的发生率以及氯吡格雷不同剂量的有效性和安全性还缺乏循证医学证据。

[ 参考文献]
[ 1 ] 　Tolleson TR,Newby LK, Harrington RA, et al. Frequency of stent thrombosis after acute coronary syndromes ( from the SYMPHONY and 2nd SYMPHONY trials) [ J ]. Am J Cardiol, 2003, 92: 330-333.
[ 2 ] 　Muller I,Besta F, Schulz C, et al. Prevalence of clop idogrel nonresponders among patientswith stable angina pectoris scheduled for elective coronary stent p lacement[ J ]. Thromb Haemost, 2003, 89: 783-787.
[ 3 ] 　Matetzky S, Shenkman B, Guetta V, et al. Clop idogrel resistance is associated with increased risk of recurrent atherothrombotic events in patientswith acute myocardial infarction[ J ]. Circulation, 2004, 109: 3171-3175.
[ 4 ] 　W iviott SD,Antman EM. Clop idogrel resistance: a new chap ter in a fast2moving story[ J ]. Circulation, 2004, 109: 3064-3067.
[ 5 ] 　Nguyen TA,Diodati JG, Pharand C, et al. Resistance to clop idogrel: a review of the evidence[ J ]. J Am Coll Cardiol, 2005, 1945 (8) : 1157-1164.
[ 6 ] 　LauWC, Gurbel PA,Watkins PB, et al. Contribution of hepatic cytochrome P4503A4 metabolic activity to the phenomenon of clop idogrel resistance [ J ]. Circulation, 2004, 109: 166-171.
[ 7 ] 　Gurbel PA,B liden KP, HiattBL, et al. Clop idogrel for coronary stenting response variability, drug resistance, and the effect of p retreatment p latelet reactivity [ J ].Circulation, 2003, 107: 2908-2913.
[ 8 ] 　Wenaweser P,DorfflerMelly J , Imboden K, et al. Stent thrombosis is associated with an impaired response to antip latelet therapy[ J ]. J Am Coll Cardiol, 2005,745 (11) : 1748-1752.
[ 9 ] 　Schumann A,W iesenburgA,Bucha E, et al. PlateletAdhesionAssay ( PADA) ,a new quantitative test for assessment of p latelet function and the apeutic drug monitoring of GPⅡb /Ⅲa and ADP recep tor antagonists[ J ]. Hamostaseologie,2004, 24 (3) : 211-216.
[ 10 ] 　Lepantalo A,Virtanen KS, Heikkila J , et al. L imited early antip latelet effect of 300mg clop idogrel in patientswith asp irin therapy undergoing percutaneous coronary interventions[ J ]. Eur Heart J , 2004, 25 (6) : 476-483.
[ 11 ] 　Rocca B, Patrono C. Determinants of the interindividual variability in response to antip latelet drugs[ J ]. J Thromb Haemost, 2005, 3 (8) : 1597-1602.
[ 12 ] 　TaubertD, KastratiA. Harlfinger S, et al. Pharmacokinetics of clop idogrel after administration of a high loading dose[ J ]. Thromb haemost, 2004, 92: 311-316.
[ 13 ] 　Steinhubl SR,Berger PB,Mann JT 3 rd, et al. Early and sustained dual oral antip latelet therapy following percutaneous coronary intervention: a randomized controlled trial[ J ]. JAMA, 2002, 288: 2411-2420.

来源：心血管病学进展  作者：李芳，肖践明，蔡乙明